C-MER Medical Holdings Limited (stock code: 03309) disclosed that on 17 October 2025, it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange, representing approximately 0.0161% of its total issued shares (excluding treasury shares) before the transaction. Following this move, the closing balance comprises 1,242,976,870 issued shares (excluding treasury shares) and 12,584,000 treasury shares, maintaining the total at 1,255,560,870.

The repurchase price ranged from HKD 1.89 to HKD 1.92 per share, amounting to a total consideration of HKD 381,360. According to the disclosure, the company holds a repurchase mandate dated 19 May 2025, authorizing the repurchase of up to 125,556,087 shares. The announcement further records multiple batches of shares repurchased for cancellation during the period from July 2024 to May 2025, although those shares have not yet been canceled. The moratorium period for any new issue or transfer of treasury shares arising from this repurchase runs until 16 November 2025.